|
|
Article: Eyes turning to Neuropathic pain market.
- Article from:
- M2 Presswire
- Article date:
- September 13, 2005
CopyrightCOPYRIGHT 2005 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-13 September 2005-DATAMONITOR: Eyes turning to Neuropathic pain market(C)1994-2005 M2 COMMUNICATIONS LTD
RDATE:14092005
London - The European and US neuropathic pain markets are currently worth a combined $2.5billion. While the majority of drugs currently used are not primarily indicated for neuropathic pain, the blockbuster status of the anticonvulsant Neurontin (gabapentin) in neuropathic pain has focused the attention of such pharmaceutical giants as Pfizer, Lilly and Boehringer Ingelheim (BI) on this potentially lucrative market and its considerable unmet needs. As such, a new report from independent market analyst Datamonitor* expects ...